Moreover, GLP-1 receptor agonist liraglutide can reduce malignant biological behavior of colorectal cancer cells by inhibiting the PI3K/Akt/mTOR signaling pathway (Tong et al., 2022). The gene discussed is GLP1R; the disease is colorectal cancer.